

UAB-20702/22
11010jks

**MUTANT PURINE NUCLEOSIDE PHOSPHORYLASE
PROTEINS AND CELLULAR DELIVERY THEREOF**

Grant Reference

The research carried out in connection with this invention was supported in
5 part by grant #U19-CA67763 from the National Cancer Institute.

Background of the Invention

Field of the Invention

This invention relates to mutant purine nucleoside phosphorylase enzymes
having different activity than the non-mutant purine nucleoside phosphorylase
10 enzyme, and to substrates for these mutant enzymes. In particular the invention
relates to a mutant M65V having greater activity than the wild-type enzyme in
cleaving specific substrates.

Description of the Related Art

A prodrug activation strategy for selectively impairing tumor cells
15 involves the expression of a gene encoding an exogenous enzyme in the tumor
cells and administration of a substrate for that enzyme. The enzyme acts on the
substrate to generate a substance toxic to the targeted tumor cells. This technique
has advantages over the expression of directly toxic genes, such as ricin,
diphtheria toxin, or pseudomonas exotoxin. These advantages include the
20 capability to (1) titrate cell impairment, (2) optimize therapeutic index by
adjusting either levels of prodrug or of recombinant enzyme expression, and (3)
interrupt toxicity by omitting administration of the prodrug. In addition, this
technique uses prodrugs found to have different effects on different cell types,
allowing treatment to be adjusted according to a specific disease state.

Enzymes useful in a prodrug activation approach have been described and include enzymes such as thymidine kinase, cytosine deaminase and purine nucleoside phosphorylase, as described in U.S. Pat. Nos. 5,338,678, 5,552,311, 6,017,896 and 6,207,150. However, the effectiveness of tumor treatment using prodrug activation techniques may be limited in cases where side-effects of substrate administration are present. For example, the prodrug ganciclovir, often used in combination with thymidine kinase, can cause unwanted immunosuppressive effects. In the case of purine nucleoside phosphorylase therapy, undesirable side-effects may occur due to the activity of endogenous human and *E. coli* purine nucleoside phosphorylases present in human cells and in normal intestinal flora respectively.

Thus, there exists a need for a prodrug activation method for treating tumors that overcomes the problem of side effects.

Summary of the Invention

A nucleotide sequence is provided that encodes a mutant purine cleaving enzyme that has different biological activity than a wild-type purine cleaving enzyme. In particular, mutant *E. coli* derived purine nucleoside phosphorylase (PNP) and nucleoside hydrolase proteins are provided. More specifically, a nucleotide sequence is described (M65V:SEQ ID NO: 1) that encodes a mutant *E. coli* derived PNP protein which has valine substituted for a methionine at position 65 (counting from the fmet) (M65V:SEQ ID NO: 2). In addition, a nucleotide sequence is provided (A157V:SEQ ID NO: 3) that encodes a mutant *E. coli* derived PNP protein which has valine substituted for an alanine at position 157

(A157V:SEQ ID NO: 4), position 157 if counting from the first. Further, mutant *E. coli* derived purine nucleoside phosphorylase (PNP) proteins are provided having different activity in cleaving a purine nucleoside analog substrate compared with a wild-type *E. coli* derived purine nucleoside phosphorylase.

5 A recombinant vector containing a nucleotide sequence of the present invention is described. Further detailed are vectors which contain a nucleotide sequence encoding a mutant *E. coli* derived purine nucleoside phosphorylase protein of the present invention. Also described is a host cell transformed with a vector of the present invention.

10 A recombinant expression vector is provided which contains the nucleotide sequence of a mutant *E. coli* derived PNP protein, M65V. Further, recombinant vectors are provided which contain the nucleotide sequence of one of the mutant *E. coli* derived PNP proteins: A157V, M65V, M65A, M65I, M65Q, H5N, A157F, A157L, E180D, E180N, E180S, E180T, M181A, M181L, M181N, M181V,
15 M181E, E182A, E182Q, E182V, D205A and D205N.

 Also provided is a recombinant virus which is capable of carrying a gene to a target cell and which contains the nucleotide sequence of a mutant purine cleaving enzyme of the present invention. Further described is a recombinant virus containing a nucleotide encoding a mutant *E. coli* derived purine cleaving
20 enzyme such as M65V. Recombinant viruses are provided which are capable of carrying a gene to a target cell and which contain a nucleotide sequence of one of the mutant *E. coli* derived PNP proteins: A157V, M65V, M65A, M65I, M65Q,

UAB-20702/22
11010jks

H5N, A157F, A157L, E180D, E180N, E180S, E180T, M181A, M181L, M181N,
M181V, M181E, E182A, E182Q, E182V, D205A and D205N.

A recombinant mutant purine cleaving enzyme having different biological
activity than a wild-type is provided. In particular, recombinant mutant *E. coli*
5 PNPs are detailed having different biological activity than a wild-type *E. coli*
PNP.

Also described is a process for impairing a cell which includes the steps of
administering a nucleotide sequence encoding a mutant purine cleaving enzyme of
the present invention to a target cell and delivering an effective amount of a
10 prodrug. More specifically, a process is provided for treatment of abnormal cell
growth and pathological viral infection by administering a mutant *E. coli* PNP to a
cell and delivering a suitable PNP substrate in order to produce a toxin and
thereby impair the cell. In particular, a process for impairing a cell is described in
which a mutant *E. coli* PNP M65V is administered to a target and an effective
15 amount of a prodrug is delivered. A process for impairing a cell is described in
which a mutant *E. coli* PNP M65V is administered to a target and an effective
amount of 9-(6,7-dideoxy- α -L-hept-6-ynofuranosyl)-6-methylpurine is delivered.
A process for impairing a cell is described in which a mutant *E. coli* PNP M65V is
administered to a target and an effective amount of 9-(α -L-lyxofuranosyl)-2-
20 fluoro-adenine is delivered. A process for impairing a cell is described in which a
mutant *E. coli* PNP M65V is administered to a target and an effective amount of
9-(6-deoxy- α -L-talofuranosyl)-6-methylpurine is delivered.

Commercials kits are described for impairing a cell which include a vector containing a nucleotide sequence encoding an amino acid sequence depicted as SEQ ID No. 2, a purified mutant PNP as depicted by SEQ ID No. 2 or a recombinant virus containing a nucleotide sequence encoding the mutant PNP depicted by SEQ ID No. 2.

Detailed Description of the Invention

The enzymes which are the subject of the present invention are purine cleaving enzymes such as purine nucleoside phosphorylases and nucleoside hydrolases. Methylthioadenosine phosphorylase is illustrative of a subclass of purine nucleoside phosphorylases also the subject of the present invention. Purine nucleoside phosphorylases and nucleoside hydrolases are present in diverse organisms illustratively including mammals such as humans, and microorganisms, such as *Leishmania donovani*; *Trichomonas vaginalis*; *Trypanosoma cruzi*; *Schistosoma mansoni*; *Leishmania tropica*; *Crithidia fasciculata*; *Aspergillus* and *Penicillium*; *Erwinia carotovora*; *Helix pomatia*; *Ophiodon elongatus*; *Salmonella typhimurium*; *Bacillus subtilis*; *Clostridium*; mycoplasma; *Trypanosoma gambiense*; *Trypanosoma brucei*; *Sulfolobus solfataricus*; *E. coli*.

A nucleoside phosphorylase catalyzes the reaction: purine analog nucleoside + PO₄ → ribose-1-PO₄ (or deoxyribose-1-phosphate) + toxic purine analog. The present invention provides nucleotide sequences and amino acid sequences encoding mutant purine cleaving enzymes having different biological activity in cleaving specific substrates compared to the wild-type enzyme. In a preferred embodiment, the purine nucleoside phosphorylase (PNP) mutants of the

present invention are genetically modified bacterial PNPs capable of reacting with a specific substrate or substrates that the native PNPs will not recognize or recognize poorly. However, any mutant purine cleaving enzyme which can selectively convert a substrate to produce a toxic purine analog can be utilized.

5 For example, as described below, a mutant *E. coli* PNP enzyme is designed according to the present invention to act on compounds with substituents on the 5'-carbon that are poor substrates for wild-type enzyme.

The term "biological activity" as used herein is intended to mean a measurement of the amount of end product produced by the reaction of a specified amount of a mutant or wild-type purine cleavage enzyme in the presence of a
10 substrate in a period of time measured by appropriate method as shown in Example 1.

A compound which is a substrate for the enzyme to produce a toxic substance which impairs a cell is referred to herein interchangeably as a "prodrug" or a "substrate."
15

The term "mutant" as used herein is intended to mean a modified protein which differs from the wild-type protein.

The term "pathogenic viral infection" as used herein is intended to mean infection by a virus causing disease or pathological effects.

20 The term "pharmaceutically acceptable" as used herein is intended to mean a material that is not biologically or otherwise undesirable, which can be administered to an individual without causing significant undesirable biological

effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.

Purine Cleavage Enzyme Mutants

Purine cleavage enzyme mutants having different biological activity than wild-type PNP in cleaving selected substrates are generated by omitting, adding, and/or exchanging at least a single amino acid for another amino acid at the same position in the PNP sequence. In a preferred embodiment, the PNP mutants have greater activity than wild-type PNP.

Mutagenesis can be performed utilizing any one of several techniques known to those of skill in the art. For example, a particular mutagenesis protocol is followed utilizing the *Quickchange Site-Directed Mutagenesis Kit* from Stratagene (La Jolla, CA). This procedure requires the use of two complementary synthetic oligonucleotide primers, each encoding the intended nucleotide change, with length and sequence also dictated by the nucleotides flanking the change site according to parameters described in the kit manual. Double-stranded plasmid DNA, comprising the DNA sequence to be mutagenized/changed, serves as the mutagenesis template. The mixed primers are annealed to heat denatured template DNA and extended using free deoxy-nucleotides and the thermostable high-fidelity *Pfu* DNA polymerase. Multiple rounds of heat denaturation, annealing and extension are performed in a thermocycler to produce adequate quantities of linear single-stranded plasmid representing each complementary strand of the plasmid template. As each de novo strand arises from the extended mutagenesis primer, it also contains the intended nucleotide change. As the complementary

strands anneal, the primary product is double-stranded plasmid, circularized by annealing through the overlap provided by the complementary primers. To eliminate the residual template DNA, the product is digested with restriction endonuclease Dpn I which selectively cleaves DNA that has been modified by in vivo methylation at its recognition site; because the in vitro synthesized mutagenesis product is not methylated, it survives the treatment with Dpn I. The newly synthesized, annealed, circularized and Dpn I digested plasmid DNA containing the nucleotide change is used to transform competent *E. coli* cells. Cell colonies arising from this transformation are screened by DNA sequence analysis to verify their containing the mutant sequence.

In a variation of the *Quickchange* procedure as described in the kit manual, the following changes can be made. The nucleotides, buffers and enzymes used may, or may not, be components of the commercially available kit. The reaction mix is made or 300 nM with each primer. After the recommended number of cycles in the thermocycler, the reaction mix is checked by electrophoresis of a small aliquot through a 0.8-1.0% agarose gel to confirm the existence of de novo plasmid DNA. Following digestion with Dpn I, excess primer is removed by purification of the plasmid DNA using the *QIAquick PCR Purification Kit* from Qiagen (Valencia, CA). The purified DNA is then heated to remove any residual primer from the linear plasmid ends, and then cooled to allow annealing of the complementary ends before transformation of the *E. coli* cells.

Mutagenesis can also be performed as described in Maniatis, et al., Molecular Cloning: A Laboratory Manual, 2nd Ed. Cold Spring Harbor, NY:

CSHL Press. In an example of such a procedure, the wild-type PNP nucleotide sequence is subcloned into a bacteriophage M13 vector and single-stranded DNA is prepared as described by Maniatis. An oligonucleotide primer is designed for each mutation. The oligonucleotide primer has the same sequence as a portion of the wild-type sequence except at the site of the desired mutation where one or two nucleotides are substituted for the wild-type nucleotides. The length of the oligonucleotide primer depends on the exact sequence in the area of the desired mutation and is determined as described in Maniatis. The mutagenic oligonucleotide primer is phosphorylated with T4 polynucleotide kinase by mixing 100-200 pmoles of the mutagenic oligonucleotide with 2 microliters of 10X bacteriophage T4 polynucleotide kinase buffer, 1 microliter of a 10 millimolar solution of ATP, 4 units of bacteriophage T4 polynucleotide kinase and water to a total reaction volume of 16.5 microliters. The 10X bacteriophage T4 polynucleotide kinase buffer is composed of 0.5 M Tris.Cl (pH 7.6), 0.1 M MgCl₂, 50 millimolar dithiothreitol, 1 millimolar spermidine HCl and 1 millimolar EDTA. The reaction is incubated for 1 hour at 37°C and then heated at 68°C for 10 minutes. The mutagenic oligonucleotide primer is annealed to single-stranded DNA in a mixture of 0.5 pmole single-stranded DNA, 10 pmoles phosphorylated mutagenic oligonucleotide, 10 pmoles nonphosphorylated universal sequencing primer complementary to a region of the vector, 1 microliter of 10X PE1 buffer and water to a total reaction volume of 10 microliters. The 10X PE1 buffer is composed of 200 millimolar Tris base, pH 7.5, 500 millimolar NaCl, 100 millimolar MgCl₂ and 10 millimolar dithiothreitol. The mixture is heated to a

temperature 20°C above the theoretical T_m of a perfect hybrid formed between the mutagenic oligonucleotide for 5 minutes. The theoretical T_m is calculated from the formula $T_m=4(G+C)+2(A+T)$. The mixture is allowed to cool to room temperature over a period of about 20 minutes. Primer extension and ligation are performed by mixing 1 microliter of 10X extension buffer (which is composed of 200 millimolar Tris base, pH 7.5, 100 millimolar $MgCl_2$, 100 millimolar dithiothreitol), 1 microliter of 10 millimolar ATP, water to 8.5 microliters, 1 microliter of a solution of the four dNTPs (dGTP, dATP, dTTP, and dCTP), each at a concentration of 2 millimolar, 5 Weiss units of T4 DNA ligase and 2.5 units of Klenow fragment of *E. coli* DNA polymerase I. Ten microliters of the primer extension/ligation mixture are added to the single-stranded DNA/oligonucleotide mixture. The reaction is then incubated at 16°C for 6-15 hours.

The reaction mixture is then used to transform *E. coli* of an appropriate strain and plaques are screened by hybridization with an appropriate labeled probe, e.g. the mutagenic oligonucleotide primer.

Specific mutants generated include: A157V, M65V, M65A, M65I, M65Q, H5N, A157F, A157L, E180D, E180N, E180S, E180T, M181A, M181L, M181N, M181V, M181E, E182A, E182Q, E182V, D205A and D205N. The DNA sequence of mutant M65V (M65V:SEQ ID NO: 1) is provided. The mutation ATG→gtt appears at bp 193. The corresponding amino acid sequence of M65V (M65V:SEQ ID NO: 2) has the position 65 methionine to valine mutation. It will be appreciated by those skilled in the art that, due to the degeneracy of the amino acid code, multiple nucleic acid sequences may encode the same amino acid

sequence. For example, valine is encoded by nucleotides gtt and by nucleotides gtc, gta and gtg. The nucleic acid codons encoding any particular amino acid are well known to those skilled in the art.

Table I summarizes the activity of 22 mutants with substrates MeP-dR and F-araA. The results are presented as the percent of wild-type activity. Of the 22 mutants in Table I, M65V, A157L, A157V and E180D retained some appreciable level of activity toward these substrates. Abbreviations used may include: MeP-dR: 9-(2-deoxy- β -D-ribofuranosyl)-6-methylpurine; F-araA: 9-(β -D-arabinofuranosyl)-2-fluoroadenine; 5'-methyl(allo)-MeP-R: 9-(6-deoxy- β -D-allofuranosyl)-6-methylpurine; 5'-methyl(talo)-MeP-R: 9-(6-deoxy- α -L-talofuranosyl)-6-methylpurine; F-Ade: 2-fluoroadenine; 5'-methyl(talo)-2-F-adenosine: 9-(6-deoxy- α -L-talofuranosyl)-2-fluoroadenine.

TABLE I

Summary of mutant *E. coli* PNP activity with MeP-dR and F-araA

	Mutant	MeP-dR	F-araA
		Percent of Control Activity	
5	Wild-type	100	100
	Not transfected	0.8	3
	H5N	0.08	0.15
	M65A	1.5	1.6
	M65I	0.02	0.15
10	M65Q	0.6	1.0
	M65V	42	37
	A157F	1.5	1.4
	A157L	12	21
	A157V	118	146
	E180D	81	60
	E180N	0.2	0.3
	E180S	0.5	0.8
	E180T	0.06	0.1
	M181A	0.04	0.2
	M181L	0.6	1.6
	M181N	0.1	0.4
	M181V	0.02	0.07
	M181E	0.04	0.1
15	E182A	0.5	0.9
	E182Q	0.6	1.0
	E182V	0.3	0.6
	D205A	1.0	1.1
	D205N	2.2	2.4

The key requirement of the mutant PNP nucleotide sequence is that it must encode a functional mutant enzyme that is able to recognize and act upon a specific substrate with different biological activity in producing a cytotoxic compound than the wild-type enzyme. Two *E. coli* mutants, M65A and M65V, are tested with various purine analog substrates with which the wild-type enzyme has lower activity than with MeP-dR, as shown in Table II.

TABLE II

Substrate	Wild-type PNP	M65A	M65V
	nmoles/mg/hour (percent of wild-type activity)		
MeP-dR	628,000	9,700 (1.5%)	—
	560,000	9,600 (1.7%)	—
	1,400,000	—	800,000 (57%)
5'methyl(allo)-MeP-R	150	13	320
	64	5	163
5'-methyl(talo)MeP-R	950	910 (96%)	—
	1630	1360 (84%)	—
	1278	—	33,600 (2600%)
	3200	2160 (68%)	>61,000 (1900%)
	2350	—	115,000 (4900%)
9-(α -L-lyxofuranosyl)-adenine	5,133	696 (14%)	—
	4,130	900 (22%)	—
	11,800	—	70,000 (593%)
5'-amino-5'-deoxy-Ado	623	29 (5%)	—
	882	—	832 (94%)

Table II shows the activity of these mutant *E. coli* PNP enzymes compared to wild-type PNP in the presence of various substrates. Activity of the M65V mutant is 38-fold greater than wild-type PNP using 5'-methyl(talo)MeP-R as a substrate and 6-fold (593%) greater than wild-type PNP using 9-(α -L-lyxofuranosyl)-adenine as a substrate. It is appreciated that the greater biological activity of the mutants will allow for greater activity in impairing abnormal cell growth when these mutants are used for treatment of pathological conditions. In addition, it is appreciated that tumors expressing the M65V *E. coli* PNP would be at least 80-fold more sensitive to 5'-methyl(talo)MeP-R or 5'-methyl(talo)-2-F-adenosine than tumors expressing wild-type PNP would be to F-araA. It is further appreciated that since the M65V mutant cleaved 5'-methyl(talo)MeP-R 80 times better than the wild-type enzyme cleaved F-araA, and since F-araA caused complete responses in tumor expressing wild-type enzyme, an at least 80-fold

UAB-20702/22
11010jks

increase in the generation of F-Ade using the M65V mutant and 5'-methyl(talo)-2-F-adenosine combination will lead to even better anti-tumor activity.

To further explore mutant activity, M65V mutant was exposed to various nucleoside analog compounds. The activity, as compared to wild-type PNP, is summarized in Table III where parenthetical data is indicative of the number of experiment measurements.

TABLE III
Activity of *E. coli* PNP mutant M65V with various nucleoside analogs

Compound	Wild type	M64V	
	Pure enzyme	crude extract	pure enzyme
nmole/mg/hr			
9-(β-D-ribofuranosyl)-6-fluoromethylpurine	56,000 (1)		211,000 (1)
9-(β-D-ribofuranosyl)-6-methylpurine	100,000 (4)		140,000 (2)
9-(2-deoxy-β-D-ribofuranosyl)-6-methylpurine	528,000 (16)	535,000 (6)	593,000 (4)
9-(2-deoxy-α-D-ribofuranosyl)-6-methylpurine	- (1*)	- (2)	
9-(β-D-arabinofuranosyl)-6-methylpurine	14 (2)	3 (2)	
9-(β-D-xylofuranosyl)-6-methylpurine	- (1*)	- (2)	
7-(β-D-ribofuranosyl)-6-methylpurine	- (2)	- (2)	
9-(α-L-lyxofuranosyl)-6-methylpurine	218 (3)		9,600 (3)
7-(α-L-lyxofuranosyl)-6-methylpurine	- (1)		- (1)
9-(6-deoxy-β-D-allofuranosyl)-6-methylpurine	47 (3)	316 (4)	
9-(6-deoxy-α-L-talofuranosyl)-6-methylpurine	915 (3)	75,000 (7)	76,000 (2)
9-(5-deoxy-5-phenylthio-β-D-ribofuranosyl)-6-methylpurine	- (2)	- (1)	
9-(6,7-dideoxy-α-L- <i>talo</i> /β-D- <i>allo</i> -hept-6-ynofuranosyl)-6-methylpurine	- (1)	119 (3)	
9-(5-deoxy-5-iodo-β-D-ribofuranosyl)-6-methylpurine	- (1)		- (1)
9-(5,5-di-C-methyl-β-D-ribofuranosyl)-6-methylpurine	- (1)		230 (1)
9-(β-D-arabinofuranosyl)-2-fluoroadenine	1,250 (6)	904 (3)	
9-(5-deoxy-5-methylthio-β-D-ribofuranosyl)-2-fluoroadenine	13 (1)		2500 (1)
9-(5-deoxy-5-iodo-β-D-ribofuranosyl)-2-fluoroadenine	13 (1)		490 (1)
9-(α-L-lyxofuranosyl)-adenine	3,690 (6)	54,000 (4)	
9-(β-D-lyxofuranosyl)-adenine	- (1)	- (2)	
9-(β-D-allopyranosyl)-adenine	- (2)	- (2)	
9-(β-D-fructopyranosyl)-adenine	- (2)	- (2)	
9-(β-D-ribofuranosyl)-adenine	- (2)	- (2)	
adenosine 5'-carboxamide	- (1)	- (2)	
5'-amino-5'-deoxyadenosine	539 (1)	930 (4)	
3'-deoxyadenosine	- (2)	- (2)	
9-(α-D-arabinofuranosyl)-adenine	- (1*)	- (2)	
2'-O-methyl-adenosine	- (2)	- (2)	
5'-deoxy-5'-methylthio-adenosine	- (2)		690 (1)
9-(2-deoxy-β-L-ribofuranosyl)-2-chloroadenine	- (1*)	- (2)	
9-(2-deoxy-α-L-ribofuranosyl)-2-chloroadenine	- (1*)	- (2)	
guanosine			778,000 (1)
9-(2,3-dideoxy-3-hydroxymethyl-α-D-ribofuranosyl)-6-thioguanine	242 (2)	- (2)	

Enzymes were mixed with 100 μM of each substrate shown in the table and the rate of cleavage was determined by HPLC separation of base from nucleoside. The numbers in parenthesis are the number of separate experiments that were averaged to obtain the value shown.

- No detectable activity at 100 μg/ml (limit of detection approximately 1 nmole/mg/hr).
* Result confirmed with crude *E. coli* PNP preparation.

UAB-20702/22
11010jks

Table IV shows the activity of five *E. coli* PNP mutant enzymes compared with wild-type (WT) PNP in the presence of various substrates.

TABLE IV

	MeP-dR	allo-met	talo-met	5'-NH ₂	allo-acet	talo-acet	α-L-lyxo	5'CONH ₂	5'-S-phenyl
WT	-	150	-	960	-	-	-	-	-
	740,000	64	962	1270	0	0	4500	18	-
	-	-	-	-	-	-	-	-	0
M65V	524,000	320	92,000	760	0	190	58,000	22	-
	281,000	163	44,700	1150	0	78	27,300	4	-
	-	-	-	-	-	-	-	-	0
M65A	12,000	13	2,400	42	0	240	1,500	23	-
	9,400	5	1160	0	0	66	1,070	3	-
M65I	260	2	30	0	0	0	118	25	-
	127	0	11	67	0	0	34	7	-
M65Q	6050	12	120	26	0	0	239	10	-
	4210	0	59	42	0	0	112	4	-
H5N	570	0	4	12	0	0	16	23	-
	280	3	0	59	0	0	11	4	-

Abbreviations - allo-met: 9-(6-deoxy-β-D-allofuranosyl)-6-methylpurine; talo-met: 9-(6-deoxy-α-L-talofuranosyl)-6-methylpurine; 5'-NH₂: 5'-amino-5'-deoxyadenosine; allo-acet: 9-(6,7-dideoxy-β-D-hept-6-ynofuranosyl)-6-methylpurine; talo-acet: 9-(6,7-dideoxy-α-L-hept-6-ynofuranosyl)-6-methylpurine; α-L-lyxo: 9-(α-L-lyxofuranosyl)-adenine; 5'-CONH₂: adenosine 5'-carboxamide; 5'-S-phenyl: 9-(5-deoxy-5-phenylthio-β-D-ribofuranosyl)-6-methylpurine; MeP-dR: 9-(2-deoxy-β-D-ribofuranosyl)-6-methylpurine; F-araA: 9-(β-D-arabinofuranosyl)-2-fluoroadenine; 5'-methyl(allo)-MeP-R: 9-(6-deoxy-β-D-allofuranosyl)-6-methylpurine; 5'-methyl(talo)-MeP-R: 9-(6-deoxy-α-L-talofuranosyl)-6-methylpurine; F-Ade: 2-fluoroadenine; 5'-methyl(talo)-2-F-adenosine: 9-(6-deoxy-α-L-talofuranosyl)-2-fluoroadenine.

Activity values are given in nmoles/mg/hour. “-” denotes no measurement was made; while “0” denotes no measurable activity.

The kinetic constants for *E. coli* PNP mutant M65V with three of the substrates of Table IV are provided herein. This kinetic data is exemplary of the precise activity of substrate compounds with the mutants of the present invention. Table V provides kinetic constants for M65V in comparison to those for wild-type PNP.

TABLE V

K_m/V_{max} determinations with wild-type and M65V *E. coli* PNP

Wild-type enzyme					
Substrate	K _m (μM)	V _{max} (nmoles/mg/hr)	r _{coef}	V _{max} /K _m	K _{cat} (min ⁻¹)
MeP-dR	140	1,810,000	0.999	12,900	723
	111	1,100,000	0.988	9,900	440
5'-methyl(talo)-MeP-R	2,980	9,116	0.999	3	4
	3,000	31,700	0.999	11	13
9-(α-L-lyxofuranosyl)-adenine	1,370	19,200	0.998	14	8
	1,340	57,700	0.978	43	23
M65V					
Substrate	K _m (μM)	V _{max} (nmoles/mg/hr)	r _{coef}	V _{max} /K _m	K _{cat} (min ⁻¹)
MeP-dR	359	2,550,000	0.997	7100	1020
	313	2,409,000	0.998	7700	963
5'-methyl(talo)-MeP-R	216	212,000	0.997	981	85
	248	252,000	0.998	1016	101
	292	255,000	0.994	873	102
9-(α-L-lyxofuranosyl)-adenine	196	215,000	0.999	1100	86
	203	162,000	0.989	798	65
	237	174,000	0.975	734	70

In yet another preferred embodiment, the PNP used in the present methods includes a modified PNP having different biological activity than wild-type PNP in cleaving substrates MeP-dR and F-araA. Mutant A157V, has a substitution of the alanine at position 158, counting the fmet as position 1, by a valine. Mutant A157V PNP has approximately 120% of the activity of wild-type PNP using MeP-

UAB-20702/22
11010jks

dR as a substrate and approximately 150% of the activity of wild-type PNP using
F-araA as a substrate.

A method is presented below by which any mutant PNP or other purine
analog nucleoside cleavage enzyme can be tested in a cell for its ability to convert
5 a given substrate from a relatively nontoxic form to a cytotoxic product.

Substrate Selection

Suitable substrates are characterized by being relatively non-toxic to a
mammalian cell compared to the toxic cleaved purine base analog. Below are
listed some illustrative examples of substrates. Common abbreviations are
10 included after some of the compounds.

9-(2-deoxy- β -D-ribofuranosyl]-6-methylpurine; MeP-dR
9-(β -D-ribofuranosyl)-2-amino-6-chloro-1-deazapurine; ACDP-R
7-(β -D-ribofuranosyl)-3-deazaguanine
9-(β -D-arabinofuranosyl)-2-fluoroadenine; F-araA, Fludarabine
15 2-fluoro-2'-deoxyadenosine; F-dAdo
9-(5-deoxy- β -D-ribofuranosyl)-6-methylpurine
2-fluoro-5'-deoxyadenosine
2-chloro-2'-deoxyadenosine; Cl-dAdo, Cladribine
5'-amino-5'-deoxy-2-fluoroadenosine
20 9-(5-amino-5-deoxy- β -D-ribofuranosyl)-6-methylpurine
9-(α -D-ribofuranosyl)-2-fluoroadenine
9-(2,3-dideoxy- β -D-ribofuranosyl)-6-methylpurine
2',3'-dideoxy-2-fluoroadenosine
9-(3-deoxy- β -D-ribofuranosyl]-6-methylpurine
25 2-fluoro-3'-deoxyadenosine

In a preferred embodiment, substrates for M65 illustratively include:

9-(α -L-lyxofuranosyl)-2-fluoroadenine
30 9-(α -L-lyxofuranosyl)-6-methylpurine

9-(6-deoxy- β -D-allofuranosyl)-6-methylpurine
9-(6-deoxy- β -D-allofuranosyl)-2-fluoroadenine
9-(6-deoxy- α -L-talofuranosyl)-6-methylpurine
35 9-(6-deoxy- α -L-talofuranosyl)-2-fluoroadenine

- 5 9-(2,6-dideoxy- β -D-allofuranosyl)-6-methylpurine
9-(2,6-dideoxy- β -D-allofuranosyl)-2-fluoroadenine
9-(2,6-dideoxy- α -L-talofuranosyl)-6-methylpurine
9-(2,6-dideoxy- α -L-talofuranosyl)-2-fluoroadenine
- 10 9-(6,7-dideoxy- α -L-hept-6-ynofuranosyl)-6-methylpurine
9-(6,7-dideoxy- α -L-hept-6-ynofuranosyl)-2-fluoroadenine
9-(6,7-dideoxy- β -D-hept-6-ynofuranosyl)-6-methylpurine
9-(6,7-dideoxy- β -D-hept-6-ynofuranosyl)-2-fluoroadenine
- 15 9-(2,6,7-trideoxy- α -L-hept-6-ynofuranosyl)-6-methylpurine
9-(2,6,7-trideoxy- α -L-hept-6-ynofuranosyl)-2-fluoroadenine
9-(2,6,7-trideoxy- β -D-hept-6-ynofuranosyl)-6-methylpurine
9-(2,6,7-trideoxy- β -D-hept-6-ynofuranosyl)-2-fluoroadenine
- 9-(2,3-dideoxy-3-hydroxymethyl- α -D-ribofuranosyl)-6-thioguanine
- 20 9-(5,5-di-C-methyl- β -D-ribofuranosyl)-2-fluoro-adenine
9-(5,5-di-C-methyl- β -D-ribofuranosyl)-6-methylpurine
- 9-(5-deoxy-5-iodo- β -D-ribofuranosyl)-2-fluoroadenine
9-(5-deoxy-5-iodo- β -D-ribofuranosyl)-6-methylpurine
- 25 9-(5-deoxy-5-methylthio- β -D-ribofuranosyl)-2-fluoroadenine
9-(5-deoxy-5-methylthio- β -D-ribofuranosyl)-6-methylpurine

Further examples are found in Ichikawa E. and Kato K., Curr Med Chem 2001 Mar;8(4):385-423. In addition, using ribose- or deoxyribose-containing substrates, *E. coli* PNP can selectively produce a variety of toxic guanine analogs, such as 6-thioguanine or 3-deazaguanine, that are attached to ribose or deoxyribose via the N-7 position in the guanine ring.

Purine analog nucleosides can be tested for activity with individual mutants according to the protocols set forth in Example 1. In a still more preferred embodiment, a substrate for mutant M65V is 9-(α -L-lyxofuranosyl)-2-fluoroadenine, 5'-methyl(talo)-MeP-R or a combination thereof.

It is appreciated that some substrates would be expected to be better tolerated than others. For example, 5'-methyl(talo)MeP-R is preferred in some cases over F-araA since it is over 40-fold less toxic to human cells in culture than F-araA. 5'-methyl(talo)MeP-R is well-tolerated when given at 200 mg/kg body weight once a day for three consecutive days in mice.

Vectors containing mutant PNP encoding nucleic acids

The present invention provides a vector containing a DNA sequence encoding a mutant *E. coli* purine nucleoside phosphorylase protein. The vector may further contain a regulatory element operably linked to the nucleotide sequence such that the nucleotide sequence is transcribed and translated in a host. Preferably, the vector is a virus or a plasmid. Illustrative examples of suitable viral vectors include a retrovirus, an adenovirus, an adeno-associated virus, a vaccinia virus, a herpes virus and a chimeric viral construction such as an adeno-retroviral vector. Among useful adenovirus vectors are human adenoviruses such as type 2 or 5 and adenoviruses of animal origin illustratively including those of avian, bovine, canine, murine, ovine, porcine or simian origin.

The use of vectors derived from adeno-associated virus for the transfer of genes in vitro and in vivo has been extensively described, for example in U.S. Pat. No. 4,797,368 and U.S. Pat. No. 5,139,941. In general, the rep and/or cap genes are deleted and replaced by the gene to be transferred. Recombinant viral particles are prepared by cotransfection of two plasmids into a cell line infected with a human helper virus. The plasmids transfected include a first plasmid containing a nucleic acid sequence encoding a mutant PNP of the present invention which is

flanked by two inverted repeat regions of the virus, and a second plasmid carrying the encapsidation genes (rep and cap) of the virus. The recombinant viral particles are then purified by standard techniques.

Also provided is a host cell transformed with a vector of the present invention.

Mutant PNP Expression

The mutant PNP enzymes of the present invention are transcribed and translated in vivo and in vitro. In order to produce the proteins in vivo, a vector containing nucleic acids encoding a specific mutant PNP is introduced into cells, in vivo or ex vivo followed by re-introduction of cells back into the animal, via a vector as outlined herein. In another embodiment, the protein of interest is produced in vitro, either in a cell or in a cell-free system. Protein produced in this manner is used in vitro or introduced into a cell or animal to produce a desired result.

Expression of a mutant PNP in mammalian cells may require a eukaryotic transcriptional regulatory sequence linked to the mutant PNP-encoding sequences. The mutant PNP gene can be expressed under the control of strong constitutive promoter/enhancer elements that are contained within commercial plasmids (for example, the SV40 early promoter/enhancer (pSVK30 Pharmacia, Piscataway, NJ, cat. no. 27-4511-01), moloney murine sarcoma virus long terminal repeat (pBPV, Pharmacia, cat. no. 4724390-01), mouse mammary tumor virus long terminal repeat (pMSG, Pharmacia, cat. no. 27-4506-01), and the cytomegalovirus early promoter/ enhancer (pCMV β , Clontech, Palo Alto, CA, cat. no. 6177-1)).

Selected populations of cells can also be targeted for destruction by using genetic transcription regulatory sequences that restrict expression of the mutant PNP coding sequence to certain cell types, a strategy that is referred to as “transcription targeting.” A candidate regulatory sequence for transcription targeting must fulfill two important criteria as established by experimentation: (i) the regulatory sequence must direct enough gene expression to result in the production of enzyme in therapeutic amounts in targeted cells, and (ii) the regulatory sequence must not direct the production of sufficient amounts of enzyme in non-targeted cells to impair the therapeutic approach. In this form of targeting, the regulatory sequences are functionally linked with the PNP sequences to produce a gene that will only be activated in those cells that express the gene from which the regulatory sequences were derived. Regulatory sequences that have been shown to fulfill the criteria for transcription targeting in gene therapy illustratively include regulatory sequences from the secretory leucoprotease inhibitor, surfactant protein A, and α -fetoprotein genes. A variation on this strategy is to utilize regulatory sequences that confer “inducibility” so that local administration of the inducer leads to local gene expression. As one example of this strategy, radiation-induced sequences have been described and advocated for gene therapy applications. It is expected that mutant PNP gene expression could be targeted to specific sites by other inducible regulatory elements.

It may be necessary to utilize tissue-specific enhancer/promoters as a means of directing mutant PNP expression, and thereby PNP-mediated toxicity, to specific tissues. For example, human tyrosinase genetic regulatory sequences are

1 sufficient to direct PNP toxicity to malignant melanoma cells. Mouse tyrosinase
sequences from the 5' flanking region (-769 bp from the transcriptional start site)
of the gene were capable of directing reporter gene expression to malignant
melanoma cells. Although the mouse and human tyrosinase sequences in the 5'
5 flanking region are similar, Shibata et al., Journal of Biological Chemistry,
267:20584-20588 (1992) have shown that the human 5' flanking sequences in the
same region used by Vile and Hart (-616 bp from the transcriptional start site) did
not confer tissue specific expression. Although Shibata et al. suggested that the 5'
flanking region would not be useful to target gene expression to tyrosinase
10 expressing cells such as melanomas or melanocytes, a slightly different upstream
fragment from that used by Shibata et al., can in fact direct reporter or bacterial
PNP gene expression specifically to melanoma cells.

Other tissue-specific genetic regulatory sequences and elements can be
used to direct expression of a gene encoding a suitable purine analog nucleoside
15 cleavage enzyme to specific cell types other than melanomas. For example, tissue-
specific promoters illustratively including a promoter of albumin, intestinal fatty
acid binding protein, milk whey, neurofilament, pyruvate kinase, smooth muscle
alpha-actin and villin.

Delivery of a mutant PNP gene

20 A mutant PNP gene of the present invention is delivered in any of a
number of forms illustratively including: DNA in the absence of any carriers or
stabilizers ("naked DNA"), DNA in the presence of pharmacologic stabilizers or

carriers (“formulated DNA”), DNA complexed to proteins that facilitate entry into the cell (“Molecular conjugates”), and DNA complexed to lipids.

5 The method of delivery of the mutant PNP gene depends on its form and a suitable method will be apparent to one skilled in the art. Such methods illustratively include administration by injection, biolistic transformation and lipofection. The use of lipid-mediated delivery of the mutant PNP gene to mammalian cells is exemplified below. More particularly, cationic liposome-mediated transfer of a plasmid containing a non-human PNP gene is demonstrated. However, other gene transfer methods will also generally be applicable because
10 the particular method for transferring the PNP gene to a cell is not solely determinative of successful tumor cell impairment. Thus, gene transduction, utilizing a virus-derived transfer vector, further described below, can also be used. Such methods are well known and readily adaptable for use in the gene-mediated toxin therapies described herein. Further, these methods can be used to target
15 certain diseases and cell populations by using the targeting characteristics of a particular carrier of the gene encoding a suitable purine analog nucleoside cleavage enzyme such as *E. coli* PNP.

Apathogenic anaerobic bacteria have been used to selectively deliver foreign genes into tumor cells. For example, *Clostridium acetobutylicum* spores
20 injected intravenously into mice bearing tumors, germinated only in the necrotic areas of tumors that had low oxygen tension. Using the assay for PNP activity described below, *Clostridium perfringens* was found to exhibit enzyme activity capable of converting MeP-dR to MeP. This finding suggests a mechanism to

selectively express mutant PNP activity in tumor masses with necrotic, anaerobic centers. Thus, tumors can be infected with strains of *Clostridium* expressing mutant PNP and then exposed to an appropriate substrate, such as 9-(α -L-lyxofuranosyl)-2-fluoroadenine, 5'-methyl(talo)-MeP-R or a combination of these.

5 The mutant PNP activity of the clostridium bacteria growing in the anaerobic center of the tumor tissue should then convert the substrate to a toxic nucleoside analog, which then is released locally to impair the tumor cells. Additionally, other bacteria including *E. coli* and *Salmonella* can be used to deliver a mutant PNP or hydrolase gene into tumors.

10 The rapidly advancing field of therapeutic DNA delivery and DNA targeting also includes vehicles such as "stealth" and other antibody-conjugated liposomes (including lipid-mediated drug targeting to colonic carcinoma), receptor-mediated targeting of DNA through cell specific ligands, lymphocyte-directed tumor targeting, and highly specific therapeutic retroviral targeting of
15 murine glioma cells *in vivo* (S.K. Huang et al., Cancer Research, 52:6774-6781 (1992); R.J. Debs et al., Am. Rev. Respir. Dis., 135:731-737 (1987); K. Maruyama et al., Proc. Natl. Acad. Sci. USA, 87:5744-5748 (1990); P. Pinnaduwaage and L. Huang, Biochemistry, 31:2850-2855 (1992); A. Gabizon and Papahadjopoulos, Proc. Natl. Acad. Sci. USA, 85:6949-6953 (1988); S. Rosenberg
20 et al., New England J. Med., 323:570-578 (1990); K. Culver et al., Proc. Natl. Acad. Sci. USA, 88:3155-3159 (1991); G.Y. Wu and C.H. Wu, J. Biol. Chem., 263, No. 29:14621-14624 (1988); Wagner et al., Proc. Natl. Acad. Sci. USA, 87:3410-3414 (1990); Curiel et al., Human Gene Ther., 3:147-154 (1992);

Litzinger, Biochimica et Biophysica Acta, 1104:179-187 (1992); Trubetskoy et al., Biochimica et Biophysica Acta, 1131:311-313 (1992)). The present approach, within the context of a gene targeting mechanism either directed toward dividing tumor cells or tumor neovascularization, offers an improved means by which a small subset of tumor cells could be established within a growing tumor mass, which would mediate rapid tumor involution and necrosis after the appropriate signal, i.e., after administration of the substrate (prodrug) for a suitable purine analog nucleoside cleavage enzyme, such as a mutant *E. coli* PNP present in or adsorbed to tumor cells.

Methods of Treatment Using a Mutant PNP Enzyme

The method of treatment basically consists of providing the mutant PNP gene to cells and then exposing the cells expressing the mutant PNP gene or protein to an appropriate substrate. The substrate is converted to a toxic substance which impairs the cells expressing the PNP gene. In addition, some cells not expressing the mutant PNP gene are exposed to the toxin and impaired. The observation that non-transfected cells are also impaired has been termed the “bystander effect” or “metabolic cooperation.” While not wishing to be limited by theory, it is thought that the toxin produced by interaction of a mutant PNP with a substrate may pass from one cell to another via nucleoside transporters.

A mutant PNP gene can be administered directly to the targeted cells or systemically in combination with a targeting means, such as through the selection of a particular viral vector, delivery formulation or other method as described above. Cells can be treated *ex vivo*, within the patient to be treated, or treated *in*

vitro, then injected into the patient. Following introduction of the PNP gene into cells in the patient, the prodrug is administered, systemically or locally, in an effective amount to be converted by the mutant PNP into a sufficient amount of toxic substance to impair the targeted cells.

5 In addition, variable dosing regimens can be used in the method of treatment. A single dose treatment is effective in producing anti-tumor effects as seen in the wild-type. Longer courses of treatment, e.g. several days to weeks, have been used in prodrug therapy with HSV-tk or CD (Ram et al., Cancer Res., 53:83-88 (1993); Dilber et al., Cancer Res., 57:1523-8 (1997); Sacco et al., Gene
10 Ther., 3:1151-1156 (1996); Beck et al., Human Gene Ther., 6:1525-30 (1995); Elshami et al., Gene Ther., 3:85-92 (1996); Fick et al., Proc. Nat. Acad. Sci. USA, 92:11071-5 (1995); Imaizumi et al., Am. J. Resp. Cell & Mole. Biol., 18:205-12 (1998); Freeman et al., Cancer Res., 53-5274-83 (1993) and Huber et al., Proc. Natl. Acad. Sci. USA, 91:8302-8306 (1994)). The disadvantage of such long-term
15 treatment is evident where there is an endogenous enzyme capable of prodrug conversion to toxin such that cells not targeted by the therapy are affected by the toxin. Thus, the inventive mutant enzymes provide a more effective method with fewer side effects compared to other prodrug/enzyme treatments.

Treatment of Pathological Conditions

20 A mutant enzyme of the present invention is used to treat a pathological condition by inhibition of targeted cells. Pathological conditions for which such treatment is efficacious illustratively include those characterized by abnormal cell growth such as that occurring in cancer of the bladder, breast, bone, colon, head or

neck, kidney, larynx, liver, lung, nasopharynx, oesophagus, ovary, pancreas, prostate, rectum, skin, stomach, thyroid, testicle and uterus as well as other conditions characterized by abnormal cell growth such as myeloid leukaemia, B lymphoma, and glioblastoma.

5 A mutant *E. coli* PNP gene is used as part of a strategy to treat metastatic solid tumors, such as melanoma, pancreatic, liver or colonic carcinoma. No effective therapy for metastatic tumors of these types currently exists. In this method, a vector containing a mutant PNP gene under the control of a tumor specific promoter is used. For example, the tyrosinase promoter is highly specific
10 for mediating expression in melanoma cells, and will not lead to transgene expression in most tissue types. The mutant PNP gene under the regulatory control of this promoter, therefore, should be activated predominantly within a melanoma tumor and not elsewhere within a patient. Promoters specific for other tumor types, for example, promoters active in the rapidly dividing endothelial
15 cells present in all solid tumors can be used to specifically activate mutant PNP specifically within a primary or metastatic tumor. In a preferred method, a vector containing mutant PNP under the control of a tumor specific promoter is delivered to cells using cationic liposomes. For example, based on animal studies, 100-400 mg plasmid DNA complexed to 1200-3600 micromoles of a 1:1 mixture of the
20 lipids DOTMA (1,2-dioleoyloxypropyl-3-trimethyl ammonium bromide) and DOPE (dioleoyl phosphatidylethanolamine) could be used to deliver the mutant PNP gene to tumor metastases in patients.

A mutant PNP gene can be used to activate prodrugs in the treatment of cancer in the central nervous system. In this method, a cell line producing retroviral particles, in which the viral particles contain the mutant *E. coli* PNP gene, is injected into a central nervous system tumor within a patient. An MRI scanner is used to appropriately inject the retroviral producer cell line to within the tumor mass. Alternatively, the isolated retrovirus particles are injected. Because the retrovirus is fully active only within dividing cells and most of the dividing cells within the cranium of a cancer patient are within the tumor, the retrovirus is primarily active in the tumor itself, rather than in non-malignant cells within the brain. Clinical features of the patient including tumor size and localization, determine the amount of producer cells to be injected. For example, a volume of producer cells in the range of 30 injections of 100 microliters each (total volume 3 ml with approximately 1×10^8 producer cells/ml injected) are given under stereotactic guidance for surgically inaccessible tumors. For tumors which can be approached intraoperatively, 100 μ l aliquots are again injected (at about 1×10^8 cells/ml) with total injected volumes up to 10 ml using a mutant *E. coli* PNP gene transfer, followed by appropriate substrate administration. This strategy is designed to permit both bystander impairment and toxicity to non-dividing cells.

The destruction of selected populations of cells can be achieved by targeting the delivery of the mutant PNP gene. A vector may contain at least a portion of a virus, bacteria, mammalian cell, non-mammalian cell, DNA molecule, or modified DNA molecule to aid delivery to target cells. The natural tropism or physiology of viral vectors can also be exploited as a means of targeting specific

cell types. For example, retroviruses are well known to become fully active only in replicating cells. This fact has been used as the basis for selective retroviral-mediated gene transfer to both human and animal replicating cancer cells growing within a site where normal cells are non-replicating. Alternatively, the viral vector can be directly administered to a specific site such as a solid tumor, where the vast majority of the gene transfer will occur relative to the surrounding tissues. This concept of selective delivery has been demonstrated in the delivery of genes to tumors in mice by adenovirus or herpes virus vectors. Molecular conjugates can be developed so that the receptor binding ligand will bind only to selective cell types, as has been demonstrated for the lectin-mediated targeting of lung cancer.

Recently, it was shown that intravenous injection of liposomes carrying DNA can mediate targeted expression of genes in certain cell types. Targeting of a gene encoding a purine analog nucleoside cleavage enzyme or expression of the gene to a small fraction of the cells in a tumor mass followed by substrate administration could be adequate to mediate involution. Through the increased production of toxin by the mutant enzyme, the present method can be used to destroy the tumor.

Treatment of virally infected cells

In addition to impairing tumor cells, the methods described herein can also be used to virally infected cells. In this embodiment, the selected gene transfer method is chosen for its ability to target the expression of the cleavage enzyme in virally infected cells. For example, virally infected cells may utilize special viral gene sequences to regulate and permit gene expression, that is, virus specific

promoters. Such sequences are not present in uninfected cells. If the mutant PNP gene is oriented appropriately with regard to such a viral promoter, the cleavage enzyme would only be expressed within virally infected cells, and not other, uninfected, cells. In another embodiment, the mutant PNP gene is delivered to
5 cells in a vector activated by trans-acting factors present only in virus-infected cells. In these cases, virally infected cells would be much more susceptible to the administration of a substrate designed to be converted to toxic form by a mutant purine nucleoside cleavage enzyme.

Thus, a target in a process for impairing a cell according to the present
10 invention includes a cell, a tissue, an organ, a tumor, a virus, a bacterium, a protozoan and combinations thereof.

Administration of genetically engineered cells

For certain applications, cells that receive the mutant PNP gene are selected and administered to a patient. This method most commonly involves *ex*
15 *vivo* co-transfer of both the gene encoding the cleavage enzyme, such as the mutant PNP gene, and a second gene encoding a therapeutic protein gene. The cells that receive both genes are reinfused into the host patient where they can produce the therapeutic protein until the prodrug, such as 9-(α -L-lyxofuranosyl)-2-fluoroadenine, 5'-methyl(talo)-MeP-R, is administered to eliminate the engineered
20 cells. This method should be useful in "cell therapies," such as those used on non-replicating myoblasts engineered for the production of tyrosine hydroxylase within the brain (Jiao et al., Nature, 362:450 (1993)).

Direct Delivery of the PNP Enzyme to Cells

The bystander impairment conferred by the mutant PNP protein plus prodrug combination can also be achieved by delivering the mutant PNP protein to the target cells, rather than the mutant PNP gene. For example, a mutant PNP enzyme capable of cleaving purine analog nucleosides as described above, is produced ex vivo by available recombinant protein techniques using commercially available reagents. As one example of a method for producing the mutant PNP protein, a mutant *E. coli* PNP coding sequence is ligated into the multiple cloning site of pGEX-4T-1 (Pharmacia, Piscataway NJ) so as to be “in frame,” with the glutathione-s-transferase (GST) fusion protein using standard techniques. The resulting plasmid contains the GST-PNP fusion coding sequence under transcriptional control of the IPTG-inducible prokaryotic *tac* promoter. *E. coli* cells are transformed with the recombinant plasmid and the *tac* promoter induced with IPTG. IPTG-induced cells are lysed, and the GST-PNP fusion protein purified by affinity chromatography on a glutathione Sepharose 4B column. The GST-PNP fusion protein is eluted, and the GST portion of the molecule removed by thrombin cleavage. All of these techniques and reagents are provided in commercially available kits, for example, one available commercially from Pharmacia, Piscataway, NJ, catalog no. 27-457001. Other methods for recombinant protein production are described in detail in published laboratory manuals.

Since the mutant PNP activates the prodrugs into diffusible toxins, it is only necessary to deliver the mutant PNP protein to the exterior of the target cells

prior to prodrug administration. The mutant PNP protein can be delivered to targets by a wide variety of techniques. One example would be the direct application of the mutant protein with or without a carrier to a target tissue by direct application, as might be done by directly injecting a tumor mass within an accessible site. Another example would be the attachment of the mutant PNP protein to a monoclonal antibody that recognizes an antigen on the tumor site. Methods for attaching functional proteins to monoclonal antibodies have been previously described. The mutant PNP conjugated monoclonal antibody is systemically administered, for example, intravenously (IV), and attaches specifically to the target tissue. Subsequent systemic administration of the prodrug will result in the local production of diffusible toxin in the vicinity of the tumor site. A number of studies have demonstrated the use of this technology to target specific proteins to tumor tissue. Other ligands, in addition to monoclonal antibodies, can be selected for their specificity for a target cell and tested according to the methods taught herein.

Another example of protein delivery to specific targets is that achieved with liposomes. Methods for producing liposomes are described e.g., Liposomes: A Practical Approach). Liposomes can be targeted to specific sites by the inclusion of specific ligands or antibodies in their exterior surface, in which specific liver cell populations were targeted by the inclusion of asialofetuin in the liposomal surface (Van Berkel et al., Targeted Diagnosis and Therapy, 5:225-249 (1991)). Specific liposomal formulations can also achieve targeted delivery, as best exemplified by the so-called Stealth™ liposomes that preferentially deliver

drugs to implanted tumors (Allen, Liposomes in the Therapy of Infectious Diseases and Cancer, 405-415 (1989)). After the liposomes have been injected or implanted, unbound liposome is allowed to be cleared from the blood, and the patient is treated with the purine analog nucleoside prodrug, such as 9-(α -L-lyxofuranosyl)-2-fluoroadenine or 5'-methyl(talo)-MeP-R, which is cleaved by a mutant *E. coli* PNP or other suitable cleavage enzyme at the targeted site. Again, this procedure requires only the availability of an appropriate targeting vehicle. In a broader sense, the strategy of targeting can be extended to specific delivery of the prodrug following either mutant PNP protein, or gene delivery.

10 Administration of substrates

The formula of Freireich et al., Cancer Chemother. Rep., 50:219-244, (1966) can be used to determine the maximum tolerated dose of substrate for a human subject. For example, based on systemically administered dose response data in mice showing that a dose of 200 mg per kg per day of 5'-methyl(talo)MeP-R for 3 days (3 doses total) was well tolerated, a human dosage of 600 mg 5'-methyl(talo)MeP-R /m² was determined according to the formula: 200 mg/kg x 3 = 600 mg/m². This amount or slightly less should be tolerated in humans with minimal side effects. Furthermore, it is understood that modes of administration that permit the substrate to remain localized at or near the site of the tumor will be effective at lower doses than systemically administered substrates.

The substrate is administered by a route determined to be appropriate for a particular subject by one skilled in the art. For example, the substrate is administered orally, parenterally (for example, intravenously), by intramuscular

injection, by intraperitoneal injection, intratumorally, or transdermally. The exact amount of substrate required will vary from subject to subject, depending on the age, weight and general condition of the subject, the severity of the disease that is being treated, the location and size of the tumor, the particular compound used, its mode of administration, and the like. An appropriate amount may be determined by one of ordinary skill in the art using only routine experimentation given the teachings herein. Generally, dosage will preferably be in the range of about 0.5-500 mg/m², when considering 5'-methyl(talo)MeP-R for example, or a functional equivalent.

Depending on the intended mode of administration, the substrate can be in pharmaceutical compositions in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, or suspensions, preferably in unit dosage form suitable for single administration of a precise dosage. Time release preparations are specifically contemplated as effective dosage formulations. The compositions will include an effective amount of the selected substrate in combination with a pharmaceutically acceptable carrier and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, or diluents.

For solid compositions, conventional nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, talc, cellulose, glucose, sucrose and magnesium carbonate. Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving or dispersing an active compound with optimal

pharmaceutical adjuvants in an excipient, such as water, saline, aqueous dextrose, glycerol, or ethanol, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, for example, sodium acetate or triethanolamine oleate. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences.

For oral administration, fine powders or granules may contain diluting, dispersing, and/or surface active agents, and may be presented in water or in a syrup, in capsules or sachets in the dry state or in a nonaqueous solution or suspension wherein suspending agents may be included, in tablets wherein binders and lubricants may be included, or in a suspension in water or a syrup. Where desirable or necessary, flavoring, preserving, suspending, thickening, or emulsifying agents may be included. Tablets and granules are preferred oral administration forms, and these may be coated.

Parenteral administration is generally by injection. Injectables can be prepared in conventional forms, either liquid solutions or suspensions, solid forms suitable for solution or prior to injection, or as suspension in liquid prior to injection or as emulsions.

The present invention provides a kit for impairing a cell that contains a vector containing a nucleotide sequence encoding an amino acid sequence depicted as SEQ ID No. 2 or a purified mutant PNP as depicted by SEQ ID No. 2 or a recombinant virus containing a nucleotide sequence encoding the mutant PNP

depicted by SEQ ID No. 2. or any combination of these, together with instructions for use of the kit. The kit further includes any reagents or components necessary for the administration of the compounds.

The following examples are given for the purpose of illustrating various
5 embodiments of the invention and are not meant to limit the present invention in any fashion.

EXAMPLE 1

Method for identifying candidate prodrugs for mutant PNP enzymes

The following method is useful to identify substrates that are cleaved more
10 efficiently by the mutant PNP than by wild-type PNP. Prodrugs identified by this method can then be further assessed by animal studies for determination of toxicity, suitability for administration with various pharmaceutical carriers, and other pharmacological properties.

The method quantitatively measures the cleavage of substrates *in vitro*.

15 The purine analog nucleosides (0.1 mM) are incubated in 500 μ l of 100 mM HEPES, pH 7.4, 50 mM potassium phosphate, and with 100 μ g/ml mutant M65V *E. coli* PNP or wild-type PNP. The reaction mixtures are incubated at 25°C for 1 hour, and the reactions stopped by boiling each sample for 2 minutes. Protein concentration and time of assay are varied depending on activity of an enzyme
20 with a particular substrate. Each sample is analyzed by reverse phase HPLC to measure conversion from substrate to product. The nucleoside and purine analogs are eluted from a Spherisorb ODSI (5 μ m) column (Keystone Scientific, Inc., State College, PA) with a solvent containing 50 mM ammonium dihydrogen phosphate

(95%) and acetonitrile (5%) and products are detected by their absorbance at 254 nm, and are identified by comparing their retention times and absorption spectra with authentic samples.

By this analysis, mutant M65V PNP has more activity for 5'-methyl(talo)-
5 MeP-R, 9-(α -L-lyxofuranosyl)-6-methylpurine and 9-(α -L-lyxofuranosyl)-adenine
than the wild-type PNP. Thus, these substrates are preferred candidate prodrugs
which are eligible for further assessment for use in the methods and compositions
described herein to treat a pathological condition. Further, mutant M65A has
more activity for 9-(6,7-dideoxy- α -L-hept-6-ynofuranosyl)-6-methylpurine than
10 does the wild-type enzyme indicating this substrate as preferable for use with this
mutant.

Any patents or publications mentioned in this specification are indicative
of the levels of those skilled in the art to which the invention pertains. These
patents and publications are herein incorporated by reference to the same extent as
15 if each individual publication was specifically and individually indicated to be
incorporated by reference.

One skilled in the art will readily appreciate that the present invention is
well adapted to carry out the objects and obtain the ends and advantages
mentioned, as well as those inherent therein. The present methods, procedures,
20 treatments, molecules, and specific compounds described herein are presently
representative of preferred embodiments, are exemplary, and are not intended as
limitations on the scope of the invention. Changes therein and other uses will

UAB-20702/22
11010jks

occur to those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.

UAB-20702/22
11010jks